6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors

Details 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors

2004-06-16

2009-02-10

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S319000

Reexamination Certificate

active

07488733

ABSTRACT:
The invention relates to novel 6-arylamino-5-cyano-4-pyrimidinones of formula (I)methods for the production thereof, and the use thereof for producing medicaments utilized for improving awareness, concentration, learning capacity, and/or retentiveness of memory. Said compounds (I) show activity as PDE9 inhibitors.

REFERENCES:
patent: 3732225 (1973-05-01), Breuer et al.
patent: 5002949 (1991-03-01), Peseckis et al.
patent: 5256668 (1993-10-01), Hsu et al.
patent: 5656629 (1997-08-01), Bacon et al.
patent: 5977118 (1999-11-01), Bacon et al.
patent: 2004/0266736 (2004-12-01), Wunder et al.
patent: 2006/0100222 (2006-05-01), Boss et al.
patent: 2006/0106035 (2006-05-01), Hendrix et al.
patent: 2006/0111372 (2006-05-01), Hendrix et al.
patent: 2007/0105876 (2007-05-01), Hendrix et al.
patent: 2007/0161662 (2007-07-01), Hendrix et al.
patent: 2 283 211 (1998-09-01), None
patent: 2 438 890 (2002-09-01), None
patent: 2 417 631 (2003-01-01), None
patent: 2 484 997 (2003-11-01), None
patent: 2 496 194 (2004-03-01), None
patent: 2 496 292 (2004-04-01), None
patent: 2 496 308 (2004-04-01), None
patent: 396 924 (1965-08-01), None
patent: 396 925 (1965-08-01), None
patent: 396 926 (1965-08-01), None
patent: 396 927 (1965-08-01), None
patent: 1 147 234 (1963-04-01), None
patent: 1 149 013 (1963-05-01), None
patent: 1 156 415 (1963-10-01), None
patent: 2 408 906 (1974-02-01), None
patent: 101 56 249 (2003-05-01), None
patent: 0 130 735 (1985-01-01), None
patent: 0 995 751 (2000-04-01), None
patent: 937726 (1963-09-01), None
patent: 95/10506 (1995-04-01), None
patent: WO 98/10765 (1998-03-01), None
patent: 98/40384 (1998-09-01), None
patent: 99/41253 (1999-08-01), None
patent: 00/18758 (2000-04-01), None
patent: 02/06288 (2002-01-01), None
patent: 02/09713 (2002-02-01), None
patent: 02/055082 (2002-07-01), None
patent: 02/068423 (2002-09-01), None
patent: 02/098864 (2002-12-01), None
patent: 03/041725 (2003-05-01), None
patent: WO 03/037899 (2003-05-01), None
patent: 03/093269 (2003-11-01), None
patent: 2004/018474 (2004-03-01), None
patent: 2004/026286 (2004-04-01), None
patent: 2004/026876 (2004-04-01), None
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Chapter 10, pp. 358 and 365, 1988.
Ulrich, Crystallization: 4. Crystal Characteristics, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002.
Lugnier, Cyclic nucleotide PDE Superfamily, Pharmacology & Therapeutics 109, pp. 366-398, 2006.
Bagli, J., et al., “Chemistry and Positive Inotropic Effect of Pelrinone and Related Derivatives. A Novel Class of 2-Methylpyridinones as Inotropic Agents”, J. Med. Chem., 31(4): 814-823 (1988).
International Search Report for corresponding international application PCT/EP2004/006477 mailed Oct. 27, 2004.
International Search Report for PCT/03/08923 mailed Dec. 15, 2003.
International Search Report for PCT/EP03/08979 mailed Nov. 25, 2003.
International Search Report for PCT/EP03/08880 mailed Apr. 16, 2004.
International Search Report for PCT/EP2004/004412 mailed Jul. 14, 2004.
International Search Report for PCT/EP2004/004455 mailed Sep. 17, 2004.
International Search Report for PCT/EP2004/014872 mailed May 19, 2005.
Ji-Ye Wei, et al; Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology (1998) vol. 56, pp. 37-64.
Douglas A. Fisher, et al; Isolation and Characterization of PDESA, A Novel Human cGMP-specific Phosphodiesterase; Journal of Biological Chemistry (1998) vol. 273, No. 25, pp. 15559-1 5564.
Michel Guipponi, et al; Identification and Characterization of a Novel Cydic Nudeotide Phosphodiesterase Gene (PDESA) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts, Genomic Structure and Sequence; Hum Genet (1998) vol. 103, pp. 386-392.
Scott H. Sonderling, et al; Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry (1998) vol. 273, No. 25, pp. 15553-15558.
Svetlana G. Andreeva, et al; Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience (2001) vol. 21, No. 22, pp. 9068-9076.
Timothy J. Martins, et al; Purification and Characterization of a Cydic GMP-stimulated Cyclic Nucledide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry (1982) vol. 257, No. 4, pp. 1973-1979.
Sharron H. Francis, et al; Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry (1980) vol. 255, No. 2, pp. 620-626.
Peter G. Gillespie, et al; Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cydic GMP-Sepharose Chromatography; Journal of Biological Chemistry (1988) vol. 263. No. 17, pp. 8133-8141.
Lindsay Fawcett, et al; Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE1 1A; Proc. Natl. Acad.Sci.(2000) vol. 97, No. 7, pp. 3702-3707.
Seiko Murashima, et al; Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme; Biochemistry (1990) vol. 29, No. 22 pp. 5285-5292.
Scott H. Sonderling, et al; Regulation of CAMP and cGMP signaling: new phosphodiesterases and new functions; Current Opinion in Cell Biology (2000) vol. 12, pp. 174-179.
Akira Miyashita, et al; Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones; Heterocycles (1990) vol. 31, No. 7, p. 1309-1314.
Kate Loughney, et al; Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated. 3′,5′-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry (1996) vol. 271, No. 2, pp. 796-806.
Guy J. Rosman, et al; Isolation and Characterization of Human cDNAs encoding a cGMPstimulated 3′,5′-Cyclic Nucleotide Phosphodiesterase; Gene (1997) vol. 191, pp. 89-95.
Takashi Miki, et al; Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family; Genomics (1996) vol. 36, pp. 476-485.
Rena Obernolte, et al; The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family; Gene (1993) vol. 129, pp. 239-247.
Kate Loughney, et al; Isolation and Characterization of cDNAs encoding PDESA, a Human cGMP-Binding, cGMP-Speafic Y.9-Cydic Nudeotide Phosphodiesterase; Gene (1998) vol. 216, pp. 139-147.
J. M. Hetman, et al; Cloning and Characterization of PDE7B, a CAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci. (2000) vol. 97, No. 1, pp. 472-476.
Douglas A. Fisher, et al; Isolation and Characterization of PDEM, a Novel Human CAMP-Specific Phosphodiesterase; Biochemical and Biophysical Research Communications (1998) vol. 246, pp. 570-577.
Kotomi Fujishige, et al; Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes R21 Both CAMP and cGMP (PDE1OA); Journal of Biological Chemistry (1999) vol. 274, No. 26, pp. 18438-.I8445.
James E. Huettner, et al; Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats; Journal of Neuroscience (1986) vol. 6, pp. 3044-3060.
Magnus Roenn, et al; Palladium (II)-Catalyzed Cyclization Using Molecular Oxygen as Reoxidant; Tetrahedron Letters (1995) vol. 36, No. 42, pp. 7749-7752.
C. C. Cheng, et al; Potential Purine Antagonists VII. Synthesis of 6-Alkylpyrazolo-[3,4-d]pyrimidines; Journal of Organic Chemistry (1958) vol. 23 pp. 191-200.
Hieke Gielen, et al; A Novel Approach to Amidines from Esters; Tetrahedron Letters (2002) vol. 43 pp. 419-421.
K. Hemender Reddy, et al; Versatile Synthesis of 6-Alkyl/Aryl-1H-Pyrazolo[3,4-d]Pyrimidin-4[5H]-Ones; Indian Journal of Chemistry (1992) vol. 31B, pp. 163-166.
Arne Schousboe, et al; Role of Ca++ and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neuogeneration: Clinical Perspective; Clinical Neuroscience (1997) vol. 4, pp. 194-198.
Rudolf Gompper, et al; Substituted Dithiocarboxylic Acids and Ketene

Affiliated with

Also associated with

Rating

6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4109966